Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 639200
                    [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
                    [Summary] => 
TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
                    [DatePublished] => 2010-12-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 628535
                    [Title] => Roche drug approved as first-line blood cancer maintenance treatment
                    [Summary] => 
BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.
                    [DatePublished] => 2010-11-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

HAL BARRON

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 639200
                    [Title] => Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance
                    [Summary] => 
TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women with early-stage HER2-positive breast cancer.
                    [DatePublished] => 2010-12-16 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 628535
                    [Title] => Roche drug approved as first-line blood cancer maintenance treatment
                    [Summary] => 
BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood cancer, who have responded to initial induction therapy.
                    [DatePublished] => 2010-11-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche drugs plus chemotherapy significantly improve rate of complete tumor disappearance

December 16, 2010 - 12:00am

TEXAS – Roche recently announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and trastuzumab plus chemotherapy in women...

Science and Environment

Roche drug approved as first-line blood cancer maintenance treatment

November 11, 2010 - 12:00am

BASEL, Switzerland — Roche announced recently that the European Commission has approved the use of rituximab as a maintenance treatment for people suffering from follicular lymphoma, a common type of blood...

Science and Environment